肿瘤干细胞分离方法的研究进展_文献综述_陈颖

[12]N ikol opoul ou A,Maina T,S otiri ou P,et al.Tetraa m ine2modified octreotide and octreotate:labeling with99m Tc and p reclinical comparis on in AR422J cells and AR422J tumor2bearing m ice[J].J Pep t Sci,2006, 12(2):1242131.

[13]Antunes P,Ginj M,Zhang H,et al.A re radi ogallium2labelled DOT A2conjugated s omat ostatin anal ogues superi or t o those labelled with other radi ometals[J]?Eur J Nucl Med Mol I m aging,2007,34(7):9822 993.

[14]GinjM,Schm itt JS,Chen J,et al.Design,synthesis,and bi ol ogi2 cal evaluati on of s omat ostatin2based radi opep tides[J].Che m B i ol,2006, 13(10):108121090.

[15]Pettinat o C,Sarnelli A,D i Donna M,et al.68Ga2DOT ANOC:bi o2 distributi on and dosi m etry in patients affected by neur oendocrine tumors [J].Eur J NuclMed Mol I m aging,2008,35(1):72279.

[16]Ginj M,Zhang H,W aser B,et al.Radi olabeled s omat ostatin re2 cep t or antagonists are p referable t o agonists f or in vivo pep tide recep t or targeting of tumors[J].Pr oc NatlAcad SciUS A,2006,103(44):164362 16441.

[17]Ferr o2Fl ores G,A rteaga de Mur phy C,Rodriguez2Cortes J,et al. Preparati on and evaluati on of99m Tc2EDDA/HY N I C2[Lys3]2bombesin for i m aging gastrin2releasing pep tide recep t or2positive tumours[J].NuclMed Commun,2006,27(4):3712376.

[18]Garcia Garayoa E,Ruegg D,B lauenstein P,et al.Che m ical and bi ol ogical characterizati on of new Re(CO)3/99m Tc(CO)3bombesin ana2 l ogues[J].NuclMed B i ol,2007,34(1):17228.

[19]Zhang H,Schuhmacher J,W aser B,et al.DOT A2PESI N,a DOT A2conjugated bombesin derivative designed for the i m aging and targe2 ted radi onuclide treat m ent of bombesin recep t or2positive tumours[J].Eur J NuclMed Mol I m aging,2007,34(8):119821208.

[20]Lantry LE,Cappelletti E,Maddalena ME,et al.177Lu2AMBA: Synthesis and charac2terizati on of a selective177Lu2labeled GRP2R agonist for syste m ic radi otherapy of p r ostate cancer[J].J Nucl Med,2006,47 (7):114421152.

[21]Baum R,Prasad V,Mutl oka N,et al.Molecular i m aging of bombe2 sin recep t ors in vari ous tumors by Ga268AMBA PET/CT:first results [J].J NuclMed,2007,48(Supp l):79P.

[22]Maes V,Garcia2Garayoa E,B lauenstein P,et al.Novel99m Tc2la2 beled neur otensin anal ogues with op ti m ized bi odistributi on p r operties[J]. J Med Che m,2006,49(5):183321836.

[23]de V isser M,Janssen PJ,Srinivasan A,et al.Stabilised111I n2la2 belled DTP A2and DOT A2conjugated neur otensin anal ogues for i m aging and therapy of exocrine pancreatic cancer[J].Eur J NuclMed Mol I m aging, 2003,30(8):113421139.

[24]Buchegger F,Bonvin F,KosinskiM,et al.Radi olabeled neur oten2sin anal og,99m Tc2NTX I,evaluated in ductal pancreatic adenocarcinoma patients[J].J NuclMed,2003,44(10):164921654.

[25]Mather SJ,McKenzie AJ,Sosabowski JK,et al.Selecti on of radi o2 labeled gastrin anal ogs for pep tide recep t or2targeted radi onuclide therapy [J].J Nucl Med,2007,48(4):6152622.

[26]GotthardtM,Behe MP,Beuter D,et al.I m p r oved tumour detecti on by gastrin recep t or scintigraphy in patients with metastasised medullary thyr oid carcinoma[J].Eur J Nucl Med Mol I m aging,2006,33(11): 127321279.

[27]GotthardtM,Behe MP,Grass J,et al.Added value of gastrin re2 cep t or scintigraphy in comparis on t o s omat ostatin recep t or scintigraphy in patients with carcinoids and other neur oendocrine tumours[J].Endocr Relat Cancer,2006,13(4):120321211.

[28]KornerM,St ockliM,W aser B,et al.G LP21Recep t or exp ressi on in human tumors and human nor mal tissues:Potential f or I n V ivo Targe2 ting[J].J NuclMed,2007,48(5):7362743.

[29]Gotthardt M,Lalyko G,van Eerd2V is male J,et al.A ne w tech2 nique f or in vivo i m aging of s pecific G LP21binding sites:First results in s mall r odents[J].Regul Pep t,2006,137(3):1622167.

[30]W ild D,Behe M,W icki A,et al.[Lys40(Ahx2DTP A2111I n)NH2] exendin24,a very p r om ising ligand for glucagon2like pep tide21(G LP21) recep t or targeting[J].J NuclMed,2006,47(12):202522033.

[31]CaiW,Zhang X,W u Y,et al.A thi ol2reactive18F2labeling agent, N2[22(4218F2fluor obenza m ido)ethyl]malei m ide,and synthesis of RG D pep tide2based tracer f or PET i m aging of al pha v beta3integrin exp ressi on [J].J Nucl Med,2006,47(7):117221180.

[32]D ijkgraaf I,Kruijtzer JA,L iu S,et al.I m p r oved targeting of the al2 pha(v)beta(3)integrin by multi m erisati on of RG D pep tides[J].Eur J NuclMed Mol I m aging,2007,34(2):2672273.

[33]D ijkgraaf I,L iu S,Kruijtzer JA,et al.Effects of linker variati on on the in vitr o and in vivo characteristics of an111I n2labeled RG D pep tide [J].NuclMed B i ol,2007,34(1):29235.

[34]D ijkgraaf I,Kruijtzer JA,Frielink C,et al.A l pha v beta3integrin2 targeting of intraperit oneally gr owing tumors with a radi olabeled RG D pep2 tide[J].I nt J Cancer,2007,120(3):6052610.

[35]de JongM,B ree man WA,Bernard BF,et al.Tumor res ponse after 90Y2DOT A02Tyr32octreotide radi onuclide therapy in a trans p lantable rat tumor model is dependent on tumor size[J].J NuclMed,2001,42(12): 184121846.

[36]Reubi JC and W aser B.Concom itant exp ressi on of several pep tide recep t ors in neur oendocrine tumours:molecular basis f or in vivo multire2 cep t or tumour targeting[J].Eur J NuclMed Mol I m aging,2003,30(5): 7812793.(2010-02-26收稿)

肿瘤干细胞分离方法的研究进展

(文献综述)

陈　颖1,2　沈　敏2　刘宝林1

干细胞是一类具有无限或者永生的自我更新能力的细

1上海理工大学医疗器械与食品学院;

2上海杨浦区安图医院检验科胞,多向分化潜能和自我更新是干细胞的两个基本特征[1]。干细胞从维持多能性到分化的分子机制的逐渐揭密,当今严重威胁生命的顽疾就会迎刃而解。对肿瘤的研究发现,恶性肿瘤细胞的生长、分化等特性与干细胞特点惊人的相似,进